A Phase I Open Label Multi Center Dose Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose Gemcitabine in Patients With Advanced Solid Malignancies
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the safety and tolerability of AZD7762 alone and in combination with Gemcitabine
Assessed after each course of treatment
Peter Langmuir, M.D.
United States: Food and Drug Administration
|Research Site||Baltimore, Maryland|
|Research Site||Battle Kreek, Michigan|